$1.00
-0.11 (-9.91%)
Open$1.08
Previous Close$1.11
Day High$1.10
Day Low$1.00
52W High$2.57
52W Low$0.88
Volume—
Avg Volume844.6K
Market Cap72.54M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,039.0% upside
Current
$1.00
$1.00
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.77M | 6.32M | 16.16M |
| Net Income | -72,532,152 | -71,452,426 | -2,032,977 |
| Profit Margin | -1,256.8% | -1,194.0% | -12.6% |
| EBITDA | -74,309,367 | -77,270,029 | -2,828,117 |
| Free Cash Flow | — | — | -1,769,464 |
| Rev Growth | -8.6% | -8.6% | -2.0% |
| Debt/Equity | 0.26 | 0.26 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |